A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer
Technology in Cancer Research & Treatment · 2024
DOI: 10.1177/15330338241249690 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Can Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma, CTLA-4 Antigen, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chunhui program of the Chinese Ministry of Education, China Lung Cancer Immunotherapy Research Project, Natural Science Foundation of Guizhou Province.
Abstract (Originalsprache)
Background
Cadonilimab (AK104) is a bispecific IgG-single-chain Fv fragment (ScFv) antibody that binds to PD-1 and CTLA-4. Cadonilimab has shown encouraging anti-tumour activity and a favourable safety profile in several tumour types. In second-line treatment, there is no defined standard of care for patients with extensive-stage small-cell lung cancer (ES-SCLC). Cadonilimab is expected to show substantial clinical efficacy.
Objective
To assess the antitumor activity and safety of cadonilimab monotherapy or combination with conventional therapy in ES-SCLC patients who failed first-line treatment.
Methods
In this multicenter, open-label, phase II study, ES-SCLC patients who had failed first-line treatment, also aged 18 years to 70 years with histologically or cytologically confirmed ES-SCLC, and an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0–2 were eligible. Patients will receive cadonilimab 10 mg/kg every three weeks (Q3 W) among 24 months until progressive disease (PD) or adverse events (AE) discovery. The primary endpoint is progression-free survival (PFS).
Trial registration
NCT05901584.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
- Department of Oncology, The First People's Hospital of Zunyi, Zunyi, Guizhou, China.
- Department of Oncology, The Second Affiliated Hospital of Guizhou Medical University, Kaili, Guizhou, China.
- Department of Oncology, Tongren People's Hospital, Tongren, Guizhou, China.
- Department of Oncology, Xingyi People's Hospital, Xingyi, Guizhou, China.
ORCID-Profile: Jian-Guo Zhou
Förderung
- Chunhui program of the Chinese Ministry of Education
- China Lung Cancer Immunotherapy Research Project
- Natural Science Foundation of Guizhou Province
- National Natural Science Foundation of China
- Youth Talent Project of Guizhou Provincial Department of Education
- Guizhou Anti-Cancer Association Fund
Zitieren
APA
Chen, C., Chen, M., Bai, Y., Li, Y., Peng, J., Yao, B., Feng, J., Zhou, J. G., & Ma, H. (2024). A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241249690
Vancouver
Chen C, Chen M, Bai Y, Li Y, Peng J, Yao B, et al. A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241249690
BibTeX
@article{Chen2024,
author = {Chen, Can and Chen, Minjun and Bai, Yuju and Li, Yajun and Peng, Jie and Yao, Biao and Feng, Jiangping and Zhou, Jian-Guo and Ma, Hu},
title = {A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
doi = {10.1177/15330338241249690}
}
EUVIMED